Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
REPL
REPL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
REPL News
US Stocks Rally as Tech Leads Gains Amid Strong Economic Signals
Jun 30 2026
NASDAQ.COM
U.S. Stocks Edge Up, Led by Technology Sector
Jun 30 2026
NASDAQ.COM
Replimune Group Reports $313.94 Million Annual Loss
Jun 29 2026
NASDAQ.COM
Replimune Reports FY GAAP EPS Miss, Cash Burn Concerns
Jun 29 2026
seekingalpha
High Options Trading Volume for Qualcomm and Replimune
Jun 26 2026
NASDAQ.COM
Replimmune's RP-1 BLA Accepted by FDA for Melanoma Treatment
Jun 26 2026
NASDAQ.COM
Replimune's RP1 Drug Application Under FDA Review
Jun 26 2026
seekingalpha
Replimune's RP1 BLA Resubmission Accepted by FDA for Review
Jun 26 2026
Newsfilter
UniQure to Seek FDA Approval for Huntington's Gene Therapy
Jun 17 2026
CNBC
UniQure to Seek Approval for Huntington's Gene Therapy
Jun 17 2026
Newsfilter
Replimune's Cancer Immunotherapy Shows Promising Early Data
Jun 01 2026
stocktwits
Replimune Receives FDA Support for BLA Resubmission
Jun 01 2026
NASDAQ.COM
Replimune Presents Final Data for RP2 Oncolytic Therapy
May 31 2026
Newsfilter
Replimune Reports Landmark Three-Year Survival Data
May 30 2026
NASDAQ.COM
Replimune Secures FDA Approval to Resubmit RP1 Application
May 30 2026
seekingalpha
Replimune Secures FDA Agreement, Shares Surge 80%
May 29 2026
stocktwits
Show More News
